回盛生物(300871) - 2021 Q4 - 年度财报

Financial Performance - The company's sales revenue from group farming customers reached RMB 609.30 million, an increase of 41.03% compared to the previous year[7]. - The company's operating revenue for 2021 was ¥996,216,817.61, representing a 28.14% increase from ¥777,458,548.09 in 2020[27]. - The net profit attributable to shareholders decreased by 11.52% to ¥132,865,534.22 in 2021, down from ¥150,156,108.11 in 2020[27]. - The company achieved a historic breakthrough in sales performance with a revenue of 996.22 million yuan, representing a year-on-year growth of 28.14%[58]. - The total revenue for 2021 was CNY 937,754,212.27, with a year-on-year increase of 31.67%[70]. - The revenue from veterinary chemical preparations was CNY 845,575,303.03, accounting for 84.88% of total revenue, with a growth of 34.64% compared to the previous year[70]. - The revenue from exports surged by 240.07% to CNY 12,865,408.39, indicating strong international demand[70]. - The revenue from South China region grew by 90.87% to CNY 211,245,158.45, highlighting market expansion efforts[70]. Cash Flow and Assets - The net cash flow from operating activities surged by 222.07% to ¥155,718,489.99, compared to ¥48,349,261.08 in the previous year[27]. - The company's cash and cash equivalents at the end of the period reached 966.14 million yuan, up 238.39% year-on-year, primarily due to funds raised from convertible bonds and operational accumulation[64]. - The company's total assets at the end of 2021 reached ¥2,741,662,030.01, a 56.47% increase from ¥1,752,225,832.51 at the end of 2020[27]. - The company's cash dividend distributed to shareholders is RMB 55,028,262.44, which accounts for 100% of the total profit distribution[172]. Research and Development - The company’s R&D expenses rose by 65.20% year-on-year to 46.89 million yuan, reflecting a strengthened focus on technological innovation[64]. - The company has established four major R&D platforms, including the Hubei Animal Health Engineering Technology Research Center, to accelerate new drug development and commercialization[119]. - The company has made significant progress in developing new veterinary drugs, with one product already on the market and another in the final stages of clinical trials[80]. - The company has established a research institute in collaboration with Huazhong Agricultural University, focusing on innovative drug development and clinical solutions[48]. Market Position and Strategy - The company has established stable partnerships with well-known domestic agricultural enterprises, enhancing its market presence and brand recognition[41]. - The company holds 143 veterinary drug approval numbers, focusing on a diverse range of products including antimicrobial and antiparasitic drugs for pigs, poultry, aquaculture, and pets[43]. - The marketing strategy combines direct sales to large-scale breeding groups and a dealer model for small and medium-sized farms, ensuring comprehensive market coverage[50]. - The company is focusing on vertical integration in the upstream raw material industry and horizontal expansion in various animal health sectors[118]. Corporate Governance - The company has a governance structure that complies with relevant laws and regulations, enhancing its operational transparency[129]. - The company has established a dedicated investor relations section on its official website, facilitating communication with investors[129]. - The company’s board consists of 5 members, including 2 independent directors, ensuring compliance with governance standards[126]. - The company has implemented a network voting platform for shareholders to express their opinions during meetings, promoting shareholder engagement[125]. Employee and Management - The total number of employees at the end of the reporting period is 828, with 376 in the parent company and 452 in major subsidiaries[164]. - The company has established a performance evaluation mechanism for senior management, ensuring that the stock incentive plan aligns with the performance and contributions of the incentive targets[178]. - The company emphasizes a performance-based salary system, including basic salaries, performance bonuses, and project incentives for research personnel[166]. - The company has a total of 8 doctoral graduates, 44 master's graduates, and 176 bachelor's degree holders among its employees[165]. Environmental and Social Responsibility - The company emphasizes environmental protection and sustainable development, adhering to regulations and promoting energy conservation and emission reduction in its operations[193]. - The company actively engages in social responsibility initiatives, including donations to educational institutions and organizing volunteer activities[195]. - The company has implemented measures to prevent fund misappropriation and ensure proper use of large funds[179]. - The company has signed a cooperation agreement with Huazhong Agricultural University, committing 100 million yuan for research in the animal protection industry, focusing on major disease prevention and new veterinary drug development[192].